Susquehanna Fundamental Investments LLC Buys New Position in ANI Pharmaceuticals, Inc. $ANIP

Susquehanna Fundamental Investments LLC bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,745 shares of the specialty pharmaceutical company’s stock, valued at approximately $724,000.

A number of other institutional investors also recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership bought a new position in shares of ANI Pharmaceuticals in the third quarter valued at approximately $32,992,000. Ranger Investment Management L.P. bought a new position in ANI Pharmaceuticals during the 2nd quarter valued at $28,406,000. Deutsche Bank AG bought a new position in ANI Pharmaceuticals during the 2nd quarter valued at $26,775,000. Balyasny Asset Management L.P. increased its position in shares of ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after purchasing an additional 276,233 shares during the period. Finally, William Blair Investment Management LLC acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at $21,372,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 2,850 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $72.80, for a total value of $207,480.00. Following the completion of the sale, the chief financial officer owned 171,843 shares in the company, valued at approximately $12,510,170.40. This represents a 1.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the transaction, the vice president directly owned 74,424 shares of the company’s stock, valued at $5,617,523.52. This represents a 0.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 27,237 shares of company stock valued at $2,155,105 over the last three months. 8.10% of the stock is owned by insiders.

ANI Pharmaceuticals Trading Up 1.6%

Shares of ANIP opened at $73.06 on Thursday. The business’s 50-day moving average price is $79.12 and its 200 day moving average price is $78.53. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.68 billion, a P/E ratio of 15.75 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a 1-year low of $70.15 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same period in the prior year, the firm earned $1.80 earnings per share. The business’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ANIP shares. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Guggenheim decreased their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Canaccord Genuity Group dropped their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.